Erratum to: Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer[Breast Cancer Res Treat, (2014), 148, 327-335, DOI 10.1007/s10549-014-3181-6];Differences in expression of proliferation-associated genes and RANKL across the menstrual cycle in estrogen receptor-positive primary breast cancer

Breast Cancer Research and Treatment

Volumn 148, Issue 2, 2014, Pages 327-335

  Haynes, Ben P ^a   Viale, Giuseppe ^c,d   Galimberti, Viviana ^d   Rotmensz, Nicole ^d   Gibelli, Bianca ^d   Smith, Ian E ^a   Dowsett, Mitch ^a,b  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c UNIVERSITY OF MILAN   (Italy)

^d EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Estradiol; Estrogen receptor; Estrogen regulated; Menstrual cycle; Premenopausal; Progesterone receptor; RANKL

Indexed keywords

ESTRADIOL; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; TRANSCRIPTION FACTOR RUNX1; ESTROGEN; ESTROGEN REGULATED PROTEIN; MESSENGER RNA; OSTEOCLAST DIFFERENTIATION FACTOR; PROGESTERONE; TUMOR MARKER; TUMOR PROTEIN;

ADULT; AGR2 GENE; ARTICLE; BREAST CANCER; CANCER RISK; CONTROLLED STUDY; ESTRADIOL BLOOD LEVEL; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC VARIABILITY; GREB1 GENE; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; ONCOGENE; PDZK1 GENE; PREMENOPAUSE; PRIMARY TUMOR; PROGESTERONE RECEPTOR GENE; RANKL GENE; RISK ASSESSMENT; RUNX1 GENE; SERPINA3 GENE; SERPINA5 GENE; SIGNAL TRANSDUCTION; TFF1 GENE; BREAST TUMOR; CANCER STAGING; CELL PROLIFERATION; ENZYME IMMUNOASSAY; FOLLOW UP; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

BIOMARKERS, TUMOR; BREAST NEOPLASMS; CELL PROLIFERATION; ESTROGENS; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOENZYME TECHNIQUES; MENSTRUAL CYCLE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; PROGESTERONE; PROGNOSIS; RANK LIGAND; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ESTROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 84911955070     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-014-3210-5     Document Type: Erratum

References (28)

1. Brinton LA, Sherman ME, Carreon JD et al (2008) Recent trends in breast cancer among younger women in the United States. J Natl Cancer Inst 100:1643–1648
2. Smith I, Dowsett M, Ebbs SR, Dixon JM, Skene A, Blohmer J-U, Ashley SE, Francis S, Boeddinghaus I, Walsh G, IMPACT Trialists Group (2005) Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, Tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen or Combined with Tamoxifen (IMPACT) multicentre double-blind randomized trial. J Clin Oncol 23:5108–5116
3. Dowsett M, Smith IE, Ebbs SR, Dixon JM, Skene A, A’Hern R, Salter J, Detre S, Hills M, Walsh G (2007) Prognostic value of Ki67 Expression after short-term presurgical endocrine therapy for primary breast cancer. J Natl Cancer Inst 99:167–170
4. Ellis MJ, Tao Y, Luo J, A’Hern R, Evans DB, Bhatnagar AS, Chaudri Ross HA, von Kameke A, Miller WR, Smith I, Eiermann W, Dowsett M (2008) Outcome prediction for estrogen receptor-positive breast cancer based on post-neoadjuvant endocrine tumour characteristics. J Natl Cancer Inst 100:1380–1388
5. Freedman OC, Amir E, Hanna W, Kahn H, O’Malley F, Dranitsaris G, Cole DE, Verma S, Folkerd E, Dowsett M, Clemons M (2010) A randomized trail exploring the biomarker effects of neoadjuvant sequential treatment with exemestane and anastrozole in post-menopausal women with hormone receptor-positive breast cancer. Breast Cancer Res Treat 119:155–161
6. Klijn JG, Beex LV, Mauriac L, van Zijl JA, Veyret C, Wildiers J, Jassem J, Piccart M, Burghouts J, Becquart D, Seynaeve C, Mignolet F, Duchateau L (2000) Combined treatment with buserelin and tamoxifen in premenopausal metastatic breast cancer: a randomized study. J Natl Cancer Inst 92:903–911
7. Jannuzzo MG, Di Salle E, Spinelli R, Pirotta N, Buchan P, Bello A (2009) Estrogen suppression in premenopausal women following 8 weeks of treatment with exemestane and triptorelin versus triptorelin alone. Breast Cancer Res Treat 11:491–499
8. Dunbier AK, Anderson H, Ghazoui Z, Folkerd EJ, A’hern R, Crowder RJ, Hoog J, Smith IE, Osin P, Nerurkar A, Parker JS, Perou CM, Ellis MJ, Dowsett M (2010) Relationship between plasma estradiol levels and estrogen-responsive gene expression in estrogen receptor-positive breast cancer in postmenopausal women. J Clin Oncol 28:1161–1167
9. Haynes BP, Viale G, Galimberti V, Rotmensz N, Gibelli B, A’Hern R, Smith IE, Dowsett M (2013) Expression of key oestrogen-regulated genes differs substantially across the menstrual cycle in oestrogen receptor-positive primary breast cancer. Breast Cancer Res Treat 138:157–165
10. Dunbier AK, Ghazoui Z, Anderson H, Salter J, Nerurkar A, Osin P, A’hern R, Miller WR, Smith IE, Dowsett M (2013) Molecular profiling of aromatase inhibitor-treated postmenopausal breast tumors identifies immune-related correlates of resistance. Clin Cancer Res 19:2775–2786
11. Tanos T, Sflomos G, Echeverria PC, Ayyanan A, Gutierrez M, Delaloye JF, Raffoul W, Fiche M, Dougall W, Schneider P, Yalcin-Ozuysal O, Brisken C (2013) Progesterone/RANKL is a major regulatory axis in the human breast. Sci Transl Med 5:182ra55
12. Gonzalez-Suarez E, Jacob AP, Jones J, Miller R, Roudier-Meyer MP, Erwert R, Pinkas J, Branstetter D, Dougall WC (2010) RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis. Nature 468(7320):103–107
13. Zurrida S, Galimberti V, Gibelli B, Luini A, Gianoglio S, Sandri MT, Passerini R, Maisonneuve P, Zucali P, Jeronesi G, Pigatto F, Veronesi U (2001) Timing of breast cancer surgery in relation to the menstrual cycle: an update of developments. Crit Rev Oncol Hematol 38:223–230
14. Weigel MT, Ghazoui Z, Dunbier A, Pancholi S, Dowsett M, Martin LA (2012) Preclinical and clinical studies of estrogen deprivation support the PDGF/Abl pathway as a novel therapeutic target for overcoming endocrine resistance in breast cancer. Breast Cancer Res 14:R78
15. Paik S, Shak S, Tang G, Kim C, Baker J, Cronin M, Baehner FL, Walker MG, Watson D, Park T, Hiller W, Fisher ER, Wickerham DL, Bryant J, Wolmark N (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817–2826
16. Parker JS, Mullins M, Cheang MC, Leung S, Voduc D, Vickery T, Davies S, Fauron C, He X, Hu Z, Quackenbush JF, Stijleman IJ, Palazzo J, Marron JS, Nobel AB, Mardis E, Nielsen TO, Ellis MJ, Perou CM, Bernard PS (2009) Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol 27:1160–1167
17. Bastien RR, Rodríguez-Lescure Á, Ebbert MT, Prat A, Munárriz B, Rowe L, Miller P, Ruiz-Borrego M, Anderson D, Lyons B, Álvarez I, Dowell T, Wall D, Seguí MÁ, Barley L, Boucher KM, Alba E, Pappas L, Davis CA, Aranda I, Fauron C, Stijleman IJ, Palacios J, Antón A, Carrasco E, Caballero R, Ellis MJ, Nielsen TO, Perou CM, Astill M, Bernard PS, Martín M (2012) PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers. BMC Med Genomics 5:44
18. Geiss GK, Bumgarner RE, Birditt B, Dahl T, Dowidar N, Dunaway DL, Fell HP, Ferree S, George RD, Grogan T, James JJ, Maysuria M, Mitton JD, Oliveri P, Osborn JL, Peng T, Ratcliffe AL, Webster PJ, Davidson EH, Hood L, Dimitrov K (2008) Direct multiplexed measurement of gene expression with color-coded probe pairs. Nat Biotechnol 26:317–325
19. Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S, Fitzgibbons PL, Francis G, Goldstein NS, Hayes M, Hicks DG, Lester S, Love R, Mangu PB, McShane L, Miller K, Osborne CK, Paik S, Perlmutter J, Rhodes A, Sasano H, Schwartz JN, Sweep FC, Taube S, Torlakovic EE, Valenstein P, Viale G, Visscher D, Wheeler T, Williams RB, Wittliff JL, Wolff AC (2010) American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795
20. Kadota M, Yang HH, Gomez B et al (2010) Delineating genetic alterations for tumor progression in the MCF10A series of breast cancer cell lines. PLoS One 5:e9201
21. Wang L, Brugge JS, Janes KA (2011) Intersection of FOXO- and RUNX1-mediated gene expression programs in single breast epithelial cells during morphogenesis and tumor progression. Proc Natl Acad Sci USA 108:E803–E812
22. Jo M, Curry TE Jr (2006) Luteinizing hormone-induced RUNX1 regulates the expression of genes in granulosa cells of rat periovulatory follicles. Mol Endocrinol 20:2156–2172
23. Anderson E, Clarke RB (2004) Steroid receptors and cell cycle in normal mammary epithelium. J Mammary Gland Biol Neoplasia 9:3–13
24. van de Vijver MJ, He YD, van’t Veer LJ, Dai H, Hart AA, Voskuil DW, Schreiber GJ, Peterse JL, Roberts C, Marton MJ, Parrish M, Atsma D, Witteveen A, Glas A, Delahaye L, van der Velde T, Bartelink H, Rutgers ET, Friend SH, Bernards R (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347:1999–2009
25. Hu H, Wang J, Gupta A, Shidfar A, Branstetter D, Lee O, Ivancic D, Sullivan M, Chatterton RT Jr, Dougall WC, Khan SA (2014) RANKL expression in normal and malignant breast tissue responds to progesterone and is up-regulated during the luteal phase. Breast Cancer Res Treat 146:515–523
26. Hosoda M, Yamamoto M, Nakano K, Hatanaka KC, Takakuwa E, Hatanaka Y, Matsuno Y, Yamashita H (2014) Differential expression of progesterone receptor, FOXA1, GATA3, and p53 between pre- and postmenopausal women with estrogen receptor-positive breast cancer. Breast Cancer Res Treat 144:249–261
27. Owen S, Ye L, Sanders AJ, Mason MD, Jiang WG (2013) Expression profile of receptor activator of nuclear-κB (RANK), RANK ligand (RANKL) and osteoprotegerin (OPG) in breast cancer. Anticancer Res 33:199–206
28. Pfitzner BM, Branstetter D, Loibl S, Denkert C, Lederer B, Schmitt WD, Dombrowski F, Werner M, Rüdiger T, Dougall WC, von Minckwitz G (2014) RANK expression as a prognostic and predictive marker in breast cancer. Breast Cancer Res Treat 145:307–315